Cart
0

Europe Continuous Glucose Monitoring Systems Market by Component (Sensors, Transmitter & Receiver, and Integrated Insulin Pumps), Demographics (Adult Population and Child Population), and End User (Diagnostics, ICUs, and Home Healthcare) - Opportunity Analysis and Industry Forecast, 2014-2022

Get 20% Free Customization In This Report
LI_16862
Pages: 162
Dec 2016 | 3193 Views
 
Author's : Pallavi Jaiswal
Tables: 27
Charts: 27
 

Europe Continuous Glucose Monitoring Systems Market Overview:

Europe Continuous Glucose Monitoring Systems Market was valued at $58 million in 2015, and is expected to reach $792 million by 2022, supported by a CAGR of 44.9% during the forecast period 2014 - 2022. The Europe continuous glucose monitoring systems market is the second largest market of the global continuous glucose monitoring systems market. Continuous glucose monitoring systems (CGMS) are used to constantly monitor glucose levels in diabetic patients, thereby helping in reducing the risk of developing long-term diabetic complications by stabilizing the elevated glucose levels.

The Europe continuous glucose monitoring systems market is expected to witness significant growth from 2016 to 2022, owing to numerous advantages of CGMS such as minimal invasiveness and real-time blood glucose monitoring. In addition, increase in per capita healthcare expenditure, increase in incidence of diabetes in Europe, and growth in purchasing power due to high disposable income of individuals are expected to fuel the EU CGMS market growth. Furthermore, the ability of CGMS to provide detailed analysis of blood glucose levels and higher precision as compared to traditional blood glucose monitoring supplements this growth. However, high costs associated with CGMS, lack of adequate reimbursement policies, and stringent government regulations restrict the global continuous glucose monitoring systems market as well as Europe continuous glucose monitoring systems market.

EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET SEGMENTATION
Europe Continuous Glucose Monitoring Systems Market Segmentation
 Get more information on this report : Request Sample Pages

The EU CGMS market report analyzes the market based on four segments: components, demographics, end users, and country. Based on component, it is categorized into sensors, transmitters & receivers, and integrated insulin pumps. Based on demographics, it is bifurcated into adult and child population. Based on end users, it is mainly classified into diagnostics/clinics, ICUs, and home healthcare. Based on country, the EU CGMS market is analyzed across Germany, France, UK, Spain, Italy, Netherlands, Norway, Sweden, Denmark, Finland, and rest of Europe.

The Europe continuous glucose monitoring systems market value is growing at a significant pace owing to the rise in diabetic population and increase in adoption rate of CGM devices. Key players focus on new product development to meet the specific requirements of the researchers. For instance, in May 2016, Senseonics Holdings Inc. received CE mark approval for Eversense CGM system that includes implantable glucose sensor, a wearable transmitter, and a mobile app.

Agreement and partnership are other key strategies adopted by the key players. These strategies between different companies, healthcare facilities, and academic institutions can positively impact the market growth. For instance, in May 2016, Senseonics signed a distributive agreement with Roche to market and sell Eversense CGM system in Germany, the Netherlands, and Italy.

Key players profiled in this report include Abbott Laboratories, DexCom Inc., Echo Therapeutics Inc., Insulet Corporation, Johnson & Johnson, Medtronic plc, Senseonics Holding Inc., and F. Hoffmann-La Roche Ltd. Other players operating in this market include AgaMatrix, Inc., GlySure, OrSense, and Ypsomed.
 
FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, 2014-2022 ($THOUSAND)
Finland Continuous Glucose Monitoring Systems Market
 Get more information on this report : Request Sample Pages
 
The Finland continuous glucose monitoring systems market is projected to grow at a CAGR of 43.9% during the forecast period. This is due to rise in incidence rate of diabetes. As per statistics of IDF Atlas 7th edition, Finland witnessed the highest number of new cases of type 1 diabetes.

KEY BENEFITS FOR STAKEHOLDERS

  • This Europe continuous glucose monitoring systems market report provides an extensive analysis of the current EU CGMS market trends and future estimations.
  • The market scenario is comprehensively analyzed with respect to the components, demographics, and end users.
  • Market estimations are based on high-end analysis of the key developments from 2014 to 2022.
  • Recent developments and key manufacturers are listed to understand the competitive market scenario.
  • In-depth analysis based on geography provides an understanding of the regional market, which assists in strategic business planning.

KEY MARKET SEGMENTS

The European continuous glucose monitoring systems market segmentation is as follows:

By Component

  • Sensors
  • Transmitters & Receivers
  • Integrated Insulin Pumps

By Demographics

  • Adult Population
  • Child Population
  • By End User
  • Diagnostics/Clinics
  • ICUs
  • Home Healthcare

By Country

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Denmark
  • Finland
  • Rest of Europe
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION
3.2. NEED FOR GLUCOSE MONITORING SYSTEMS

3.2.1. Diabetesa pandemic

3.2.1.1. Type 1 diabetes
3.2.1.2. Type-2 diabetes
3.2.1.3. Prediabetes and gestational diabetes mellitus (GDM)
3.2.1.4. Gestational diabetes mellitus (GDM)
3.2.1.5. Secondary diabetes
3.2.1.6. Global healthcare expenditure on diabetes

3.3. TECHNOLOGICAL ADVANCEMENTS IN CGMS

3.3.1. Smartphone-connected CGMS

3.3.1.1 Wearable and smartphone-connected CGMS
3.3.1.2. 'Smart diabetes management solutionbionic/artificial pancreas
3.3.1.3. Non-invasive CGMS
3.3.1.4. Invasive CGMS

3.3.2. CGMS: PRIME END USER SEGMENTS

3.3.2.1. CGMS: role in intensive care units (ICUs)

3.3.2.1.1. Stress hyperglycemia: common occurrence in ICUs

3.3.2.2. Non-standardization and erroneous glycemic control across ICUs
3.3.2.3. Benefits and driving factors of CGMS in ICUs

3.3.2.3.1. Use of CGMS for tight glycemic control in ICUs
3.3.2.3.2. Cost benefits due to use of CGMS
3.3.2.3.3. Lower effectiveness of POC glucometers than CGMS in ICUs
3.3.2.3.4. CGMS: most preferred by ICU staff

3.4. KEY FINDINGS

3.4.1. Top investment pockets

3.4.1.1. CGMS market, by components

3.4.2. Top winning strategies

3.5. PATENT ANALYSIS
3.6. MARKET SHARE ANALYSIS, 2015
3.7. GOVERNMENT REGULATIONS

3.7.1. ISO regulations (ISO 13485:2003)

3.7.1.1. Objective and Scope of ISO 13485:2003

3.8. EUROPE REIMBURSEMENT SCENARIO

3.8.1. Germany
3.8.2. France
3.8.3. UK
3.8.4. Spain
3.8.5. Italy

3.9. MARKET DYNAMICS

3.9.1. Drivers

3.9.1.1. Benefits of CGMS over POC glucometers
3.9.1.2. Rise in incidence of diabetes cases
3.9.1.3. Technological advancements

3.9.2. Restraints

3.9.2.1. Adverse effects and accuracy
3.9.2.2. Reimbursement and stringent regulatory issues

3.9.3. Opportunities

3.9.3.1. High adoption rate of CGMS in home healthcare and ICUs
3.9.3.2. Increase in product awareness
3.9.3.3. High undiagnosed patient population

Chapter: 4 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SENSORS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. TRANSMITTERS & RECEIVERS

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INTEGRATED INSULIN PUMPS

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKETBY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14 YEARS)

5.2.1. Market size and forecast

5.3. CHILDREN POPULATION (14 YEARS)

5.3.1. Market size and forecast

Chapter: 6 EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. DIAGNOSTIC CENTERS/CLINICS

6.2.1. Market size and forecast

6.3. ICUS

6.3.1. Market size and forecast

6.4. HOME HEALTHCARE

6.4.1. Market size and forecast

Chapter: 7 CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY

7.1. OVERVIEW

7.1.1. Key market trends
7.1.2. Key growth factors and opportunities
7.1.3. Market size and forecast
7.1.4. Germany

7.1.4.1. Market size and forecast

7.1.5. France

7.1.5.1. Market size and forecast

7.1.6. UK

7.1.6.1. Market size and forecast

7.1.7. Spain

7.1.7.1. Market size and forecast

7.1.8. Italy

7.1.8.1. Market size and forecast

7.1.9. Norway

7.1.9.1. Market size and forecast

7.1.10. Sweden

7.1.10.1. Market size and forecast

7.1.11. Denmark

7.1.11.1. Market size and forecast

7.1.12. Finland

7.1.12.1. Market size and forecast

7.1.13. Netherlands

7.1.13.1. Market size and forecast

7.1.14. Rest of Europe

7.1.14.1. Market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Overview
8.1.2. Operating business segments
8.1.3. Business performance
8.1.4. Key strategic moves and developments

8.2. DEXCOM, INC.

8.2.1. Overview
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. ECHO THERAPEUTICS, INC.

8.3.1. Overview
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. F. HOFFMANN-LA ROCHE LTD.

8.4.1. Overview
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. INSULET CORPORATION

8.5.1. Overview
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. JOHNSON & JOHNSON

8.6.1. Overview
8.6.2. Operating business segments
8.6.3. Business performance
8.6.4. Key strategic moves and developments

8.7. MEDTRONIC PLC

8.7.1. Overview
8.7.2. Operating business segments
8.7.3. Business performance
8.7.4. Key strategic moves and developments

8.8. SENSEONICS HOLDINGS, INC.

8.8.1. Overview
8.8.2. Key strategic moves and developments

LIST OF TABLES

TABLE 1. FEATURES OF CURRENTLY AVAILABLE STAND-ALONE CGM SYSTEMS (2016)
TABLE 2. FEATURES OF CURRENTLY AVAILABLE INTEGRATED CGM SYSTEMS (2016)
TABLE 3. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 4. EUROPE CONTINUOUS GLUCOSE MONITORING SENSORS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 5. EUROPE CONTINUOUS GLUCOSE MONITORING TRANSMITTERS AND RECEIVERS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 6. EUROPE CONTINUOUS GLUCOSE MONITORING INTEGRATED INSULIN PUMPS MARKET, BY COUNTRY, 20142022 ($THOUSAND)
TABLE 7. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 8. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ADULT POPULATION (>14YEARS), BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 9. TYPE-1 DIABETES (014 YEARS), 2015
TABLE 10. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR CHILD POPULATION (14YEARS), BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 11. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 12. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR DIAGNOSTICS/CLINICS, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 13. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR ICUS, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 14. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET FOR HOME HEALTHCARE, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 15. PREVALENCE ESTIMATES OF DIABETES (2079 YEARS) IN EUROPE, 2015
TABLE 16. EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COUNTRY, 2014-2022 ($THOUSAND)
TABLE 17. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 18. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 19. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 20. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 21. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 22. FRANCE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 23. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 24. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 25. UK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 26. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 27. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 28. SPAIN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 29. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 30. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 31. ITALY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 32. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 33. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 34. NORWAY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 35. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 36. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 37. SWEDEN CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 38. DENMARK CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 39. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 40. GERMANY CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 41. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 42. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 43. FINLAND CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 44. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 45. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 46. NETHERLANDS CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 47. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTMES MARKET, BY COMPONENTS, 2014-2022 ($THOUSAND)
TABLE 48. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY DEMOGRAPHICS, 2014-2022 ($THOUSAND)
TABLE 49. REST OF EUROPE CONTINUOUS GLUCOSE MONITORING SYSTEMS MARKET, BY END USER, 2014-2022 ($THOUSAND)
TABLE 50. ABBOTT: COMPANY SNAPSHOT
TABLE 51. ABBOTT: OPERATING SEGMENTS
TABLE 52. DEXCOM: COMPANY SNAPSHOT
TABLE 53. ECHO THERAPEUTICS: COMPANY SNAPSHOT
TABLE 54. ROCHE: COMPANY SNAPSHOT
TABLE 55. INSULET: COMPANY SNAPSHOT
TABLE 56. JNJ: COMPANY SNAPSHOT
TABLE 57. JNJ: OPERATING SEGMENTS
TABLE 58. MEDTRONIC: COMPANY SNAPSHOT
TABLE 59. MEDTRONIC: OPERATING SEGMENTS
TABLE 60. SENSEONICS: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. PREVALENCE OF TYPE 1 DIABETES (AGE GROUP OF <15 YEARS), BY GEOGRAPHY (2015)
FIGURE 2. GLOBAL PREVALENCE OF TYPE-2 DIABETES (2014)
FIGURE 3. SIMILAR PREDISPOSITION AND RISK FACTORS FOR PREDIABETES AND TYPE-2 DIABETES
FIGURE 4. TOP TEN COUNTRIES/TERRITORIES FOR DIABETES-RELATED HEALTH EXPENDITURE, 2015
FIGURE 5. GLOBAL FINANCIAL BURDEN OF DIABETES, BY GEOGRAPHY
FIGURE 6. OCCURRENCE OF HYPERGLYCEMIA IN ICUS
FIGURE 7. TOP INVESTMENT POCKETS IN CGMS, BY COMPONENTS SEGMENT
FIGURE 8. TOP WINNING STRATEGIES IN EUROPE CGMS MARKET: PERCENTAGE DISTRIBUTION (20142016)
FIGURE 9. TOP WINNING STRATEGIES IN EUROPE CGMS MARKET, BY TYPE (20142016)
FIGURE 10. PATENTS REGISTERED/APPROVED IN THE WORLD THROUGH 2016
FIGURE 11. MARKET SHARE ANALYSIS OF EUROPE CGMS MARKET, 2015
FIGURE 12. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
FIGURE 13. ABBOTT: REVENUE, BY YEAR ($MILLION)
FIGURE 14. ABBOTT: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 15. ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 16. DEXCOM: REVENUE, BY YEAR ($MILLION)
FIGURE 17. DEXCOM: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 18. ECHO THERAPEUTICS: REVENUE, BY YEAR ($MILLION)
FIGURE 19. ROCHE: REVENUE, BY YEAR ($MILLION)
FIGURE 20. ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 21. INSULET: REVENUE, BY YEAR ($MILLION)
FIGURE 22. JNJ: REVENUE, BY YEAR ($MILLION)
FIGURE 23. JNJ: REVENUE, BY SEGMENT, 2015 (%)
FIGURE 24. JNJ: REVENUE, BY GEOGRAPHY, 2015 (%)
FIGURE 25. MEDTRONIC: REVENUE, BY YEAR ($MILLION)
FIGURE 26. MEDTRONIC: REVENUE BY SEGMENT, 2016 (%)
FIGURE 27. MEDTRONIC: REVENUE BY GEOGRAPHY, 2016 (%)

 

The European continuous glucose monitoring systems market consists of systems that manage diabetes by providing real-time glucose levels and alert the patients in case of hypo- or hyperglycemia. This helps reduce the probability of any complications related to diabetes. Geriatric patients tend to skip or forget their hypoglycemic medications; in such cases, CGMS devices automatically deliver the insulin dosage. Owing to these reasons, geriatric patients are more amenable to integrated CGMS devices that help maintain tight glycemic control (TGC) and auto-deliver insulin as per the circadian clock.

Growth in demand for advanced CGMS devices has revolutionized this technology. For instance, smartphone-connected CGMS are devices that connect with a smartphone’s built-in activity monitor, GPS, scheduling systems, contacts, camera, and voice activation, and sub-sequentially display results and trend analyses. Non-invasive CGMs such as Symphony CGM System have gained importance owing to their user-friendliness, widespread applications, and FDA approvals for these products. Bionic pancreas, a smart and a complete diabetes management solution majorly for Type I diabetes patients aged 14 years and older, was the ultimate objective in terms of technological evolution of the CGMS, which is achieved by Medtronic plc. On September 2016, Medtronic received FDA approval for its MiniMed 670G hybrid closed loop system, an artificial pancreas, which is yet to be approved for use in European countries.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Europe Continuous Glucose Monitoring Systems Market- Opportunity Analysis and Industry Forecast, 2014-2022

  • Online Only
  • $2819
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3132
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $4032
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $4843
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $6754
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo